Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.The US Department of Justice (DoJ) has said that it will not challenge efforts by drugmakers to share information to scale up the manufacturing of monoclonal antibody treatments for Covid-19.
The DoJ sent a letter to Eli Lilly, Amgen, AbCellera Biologics, AstraZeneca, Genentech and GlaxoSmithKline, noting that the demand for monoclonal antibodies against Covid-19 is likely to be higher than what one company could produce on its own.
In addition, waiting until regulatory approvals before manufacturing scale-up might delay access to the therapies by many months, in turn impacting the country’s response against Covid-19.